Dynavax Technologies | DVAX - Stock


Dynavax Technologies reported $75.69M in Stock for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Stock Change Date
AbbVie USD 4.53B 345M Mar/2025
Adma Biologics USD 191.46M 21.22M Jun/2025
Amgen USD 6.58B 146M Jun/2025
AstraZeneca USD 6.47B 583M Jun/2025
Biogen USD 2.27B 400K Jun/2025
BioMarin Pharmaceutical USD 1.34B 65.32M Jun/2025
Bristol-Myers Squibb USD 2.74B 71M Jun/2025
Dynavax Technologies USD 75.69M 1.28M Jun/2025
Gilead Sciences USD 1.83B 66M Jun/2025
Glaxosmithkline GBP 6.07B 403M Jun/2025
Merck USD 6.6B 405M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Novartis USD 6.31B 478M Jun/2025
Pfizer USD 11.67B 817M Jun/2025
Regeneron Pharmaceuticals USD 3.21B 760.7M Jun/2025
Roche Holding CHF 7.61B 339M Dec/2024
Sarepta Therapeutics USD 994.04M 52.6M Jun/2025
TG Therapeutics USD 155.2M 2.56M Jun/2025
Vertex Pharmaceuticals USD 1.5B 139.6M Jun/2025